HSPD1 and lip and oral cavity carcinoma: Furthermore, patients with low HSPD1/low E-cadherin expression still have better survival [DSS AHR = 1.49 (0.75–2.96); DFS AHR = 1.16 (0.60–2.26), Table 3] compared to patients with high HSPD1/low E-cadherin expression [DSS AHR = 2.24 (1.32–3.83); DFS AHR = 1.88 (1.13–3.14), Table 3], which supports the notion that low HSPD1/low E-cadherin expression has protective effects in oral cancer patients although it is not significant different.